Costco is stepping further into the healthcare space with a move that could disrupt both retail pharmacies and drug pricing. The company has partnered with Novo Nordisk to offer members access to Wegovy and Ozempic at a major discount. The collaboration was first reported by Fox Business, which published statements from Novo Nordisk leadership confirming the deal.
The Deal
Through the Costco Member Prescription Program, members with a prescription can purchase a four-week supply of either medication for $499 out of pocket. That rate matches Novo Nordisk’s existing self-pay pricing shown on its official channels, including the company’s website. Details about the offer can be found through Novo Nordisk’s pricing resources. Executive Members and Costco Citibank Visa cardholders may qualify for additional savings depending on program terms.
How These Drugs Became Household Names
Wegovy and Ozempic surged in popularity as more patients began turning to GLP-1 treatments for diabetes and weight management. Wegovy was approved by the FDA in 2021 specifically for chronic weight management, and that authorization is documented in the FDA’s approval announcement. Ozempic is approved to treat Type 2 diabetes, but both medications use semaglutide as the active ingredient. These drugs work by activating GLP-1 receptors, which regulate insulin release, slow digestion, and reduce appetite.
What It Means for Consumers
Cost has been one of the biggest barriers to access. Without insurance, the monthly price of Wegovy or Ozempic often ranges from $900 to $1,400, according to data published by GoodRx. Costco’s $499 price point does not eliminate the need for out-of-pocket payment, but it brings costs closer to reach for people who lack coverage or face high deductibles.
Prescriptions are still required, and insurance cannot be applied to the offer. However, this move may push other retailers, insurers, and pharmacy programs to revisit their pricing or coverage strategies.
Why This Move Matters
Costco has built a reputation around affordability and trust. By expanding into prescription-based healthcare, the retailer is signaling a broader strategy that could increase loyalty and foot traffic. Novo Nordisk, meanwhile, strengthens its U.S. distribution and reaches a growing market of patients interested in GLP-1 medications.
For investors, two trends stand out:
- Retail giants like Costco are expanding deeper into healthcare services.
- Drugmakers are partnering with consumer brands to scale access and compete on price.
Final Word
For Costco members, this isn’t just another perk — it’s an opportunity to access high-demand medications at a significantly lower cost. For the market, it’s another step toward retail-driven healthcare, where affordability, convenience, and competition collide.
About Author
